Literature DB >> 26435907

Primary hepatic mucosa-associated lymphoid tissue lymphoma: a case report and literature review.

Shigeyuki Nagata1, Norifumi Harimoto1, Kiyoshi Kajiyama1.   

Abstract

Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma is an extremely rare disease. We herein describe the findings in a 74-year-old man with elevated liver enzyme levels. Dynamic computed tomography showed focal biliary dilation and atrophy in the posterior segment, while dynamic magnetic resonance images revealed a small, highly enhanced small mass located at the root of posterior branch of the biliary ducts. As the mass was not detected on abdominal ultrasonography, a biopsy could not be performed. Cholangiocellular carcinoma was suspected, and surgery was performed. However, the surgically resected hepatic tumor was a nodule of aggregated lymphocytes that formed a lymphoepithelial lesion. Immunohistochemical analysis revealed that the lymphoma cells were positive for CD20 and CD79a, but negative for CD3. No other lymphoid lesions were found during additional postoperative examinations. Therefore, the patient was diagnosed with primary hepatic MALT lymphoma. He was also diagnosed with Helicobacter pylori infection, and thus, pylorus eradication was performed. At the time of this report, the patient was free of disease for 2 years without any additional treatment. The present case contributed to the diagnosis and management of this rare disease, as previously published case reports described varying imaging features; it also suggested that preoperative diagnosis was often difficult without biopsy.

Entities:  

Keywords:  Helicobacter pylori; Hepatectomy; Mucosa-associated lymphoid tissue lymphoma; Primary hepatic lymphoma

Year:  2015        PMID: 26435907      PMCID: PMC4580714          DOI: 10.1186/s40792-015-0091-8

Source DB:  PubMed          Journal:  Surg Case Rep        ISSN: 2198-7793


Background

Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade malignant lymphoma that was first described by Isaacson and Wright in 1983 [1]. The stomach is one of the most common sites of MALT lymphoma development, and gastric MALT lymphoma is commonly associated with Helicobacter pylori (HP) infection. However, primary hepatic lymphoma (PHL) is very rare, accounting for approximately only 0.016 % of all cases of all non-Hodgkin’s lymphoma cases [2]. Furthermore, primary hepatic MALT lymphoma is extremely rare among the diagnosed PHL cases. In addition, the standard diagnostic method and treatment strategy of this disease have yet to be established. Herein, we describe a case of surgically resected primary hepatic MALT lymphoma, which was initially suspected to be a cholangiocellular carcinoma, and review the relevant literature.

Case presentation

A 74-year-old man was referred to our department for mild elevation of liver enzyme levels. He had no significant medical history except for hypertension that was medically managed. His family history was unremarkable. Physical examination at presentation did not indicate any abnormalities. The laboratory tests conducted at our hospital showed the following findings: hemoglobin level of 17.4 g/dl, a platelet count of 204,000/μl, albumin level of 4.5 g/dl, total bilirubin level of 0.6 mg/dl, aspartate aminotransferase level of 22 IU/L, alanine aminotransferase level of 34 IU/L, lactate dehydrogenase level of 160 IU/L, γ-glutamyltranspeptidase level of 36 IU/L, alkaline phosphatase level of 338 IU/L, C-reactive protein level of 0.43 mg/dl, IgG level of 2199 mg/dl, and IgM level of 268.7 mg/dl. Hepatitis B surface antigen and anti-hepatitis C virus antibody in the serum were negative. Anti-nuclear antibody and anti-mitochondrial antibody were also negative. Tumor marker levels including carcinoembryonic antigen, carbohydrate antigen 19-9, α-fetoprotein, and des-γ-carboxy prothrombin were within the normal ranges. Dynamic computed tomography (CT) with drip infusion cholangiography revealed focal dilatation of the biliary ducts and atrophy in the posterior segments of the liver without any observable mass (Fig. 1a, b). The magnetic resonance imaging (MRI) scans, T1- and T2-weighted images, did not show any mass. However, when gadolinium was used as a contrast agent, a 1.5-cm mass located in the area adjacent at the main posterior biliary duct was highly enhanced on T1-weighted images during the arterial phase but demonstrated rapid withdrawal in the portal venous and delayed phases (Fig. 2). Gastroscopic and colonoscopic examinations showed no ulcerative or tumorous lesion. As the mass was not detected on abdominal ultrasonography (US) and it could possibly be a malignant tumor such as cholangiocellular carcinoma, the patient consented to undergo a right hepatectomy with lymph node dissection in the hepatic portal region. Grossly, a 7-mm white mass detected along with the posterior biliary duct was soft and non-encapsulated like a lymph follicle (Fig. 3a).
Fig. 1

Computed tomography findings. a Dynamic computed tomography with drip infusion cholangiography revealed focal dilatation of the biliary ducts (arrow) and atrophy (arrowheads) in the posterior segments of the liver. b No tumor was detected via enhanced computed tomography

Fig. 2

Enhanced magnetic resonance imaging after gadolinium injection. The tumor was hyper-intense on T1-weighted images (arrow) in the area adjacent to the main posterior biliary duct in the arterial phase but showed rapid washout in the late phase

Fig. 3

Tumor characteristics. a Grossly, the 7-mm white mass along the posterior biliary duct was soft and non-encapsulated. b Histological findings on hematoxylin and eosin staining. The lesion consisted of dense lymphocyte infiltration with some lymph follicles. c and d Small to mid-sized lymphocytes formed lymphoepithelial lesions on some bile capillaries

Computed tomography findings. a Dynamic computed tomography with drip infusion cholangiography revealed focal dilatation of the biliary ducts (arrow) and atrophy (arrowheads) in the posterior segments of the liver. b No tumor was detected via enhanced computed tomography Enhanced magnetic resonance imaging after gadolinium injection. The tumor was hyper-intense on T1-weighted images (arrow) in the area adjacent to the main posterior biliary duct in the arterial phase but showed rapid washout in the late phase Tumor characteristics. a Grossly, the 7-mm white mass along the posterior biliary duct was soft and non-encapsulated. b Histological findings on hematoxylin and eosin staining. The lesion consisted of dense lymphocyte infiltration with some lymph follicles. c and d Small to mid-sized lymphocytes formed lymphoepithelial lesions on some bile capillaries Histologically, dense lymphocyte infiltration with some lymphoid follicles was observed in the portal area (Fig. 3b). Small- to middle-sized lymphocytes showed no apparent atypia but formed lymphoepithelial lesions on some bile capillaries (Fig. 3c, d). Immunohistochemical studies indicated that the lymphocytes were positive for CD20 and CD79a (Fig. 4), but negative for CD3. The patient was diagnosed with low-grade hepatic MALT lymphoma based on the abovementioned pathological findings.
Fig. 4

Histological findings by immunohistochemical staining. Lymphocytes were diffusely positive for CD20 and CD79a antibodies

Histological findings by immunohistochemical staining. Lymphocytes were diffusely positive for CD20 and CD79a antibodies Subsequently, the patient’s level of interleukin-2 receptor was found to be elevated at 1133 U/ml (normal range, 122–496 U/ml). He was also infected with HP and medical treatment for pylorus eradication was provided. Biopsy of the bone marrow revealed a normoplastic marrow. Positron emission tomography demonstrated diffuse accumulation in both the thyroid glands, with a maximum standardized uptake value of 4.0. Biopsy of the thyroid glands showed chronic thyroiditis without malignancy, and the patient’s thyroid function was within normal limits. The present case of MALT lymphoma was diagnosed a stage I tumor, according to the Ann Arbor classification, and careful follow-up without additional treatment was selected. At the time of this report, the patient remained alive and free of disease 2 years after surgery.

Discussion

MALT lymphoma often develops at several anatomic sites, including the gastrointestinal tract, lungs, head and neck, skin, thyroid glands, breasts, and liver. Gastric MALT lymphoma is thought to be triggered by chronic inflammation, which can occur in different diseases including chronic gastritis associated with HP infection, Sjogren syndrome, and Hashimoto thyroiditis [3]. The etiology of primary hepatic MALT lymphoma is unclear, but it has been reported that primary biliary cirrhosis [4-8], hepatitis C viral infection [8-13], hepatitis B viral infection [14-16], ascariasis [17, 18], and HP infection [19] are possibly related with the pathogenesis of hepatic MALT lymphoma. At presentation, our patient was not infected with hepatitis viruses, and his thyroid function and bone marrow were normal. He was also negative for anti-nuclear and anti-mitochondrial antibodies. However, his serum IgG and IgM levels were elevated, and he showed HP infection. Such clinical findings suggested that the hepatic MALT lymphoma might be strongly associated with chronic inflammation caused by HP infection. Subsequent treatment for HP infection after surgery was successful. For literature review, we searched PubMed and Ichushi Web by Japan Medical Abstracts Society independently. Key terms used included “MALT lymphoma,” “liver,” “hepatic MALT lymphoma,” and “primary hepatic lymphoma. To our knowledge, there are 37 reports including 51 patients with primary hepatic MALT lymphoma [4-41] (Table 1). The mean age of these 22 men and 29 women was 64.0 years. In most cases, the hepatic tumors were incidentally detected during surgical resection or on follow-up imaging examination for liver diseases or other conditions. In 24 patients (47 %), liver diseases concomitantly existed (ascariasis, 2; primary biliary cirrhosis, 5; hepatitis B, 4; hepatitis C, 6; drug induced hepatitis, 1; cirrhosis without hepatitis viral infection, 5; and multiple biliary cysts, 1). Thus, hepatic MALT lymphoma development might be related to chronic liver inflammation, similar to gastric MALT lymphoma. Thirty-eight patients (74 %) had solitary mass, and the tumor size was ≤3 cm in 22 of the 41 reported cases (53 %). Regarding radiological characteristics, in 15 cases, the tumors were described as detectable hypo-echoic masses via abdominal US. In 21 cases, they were detected as low-density masses via CT, including 6 cases with enhancement and 9 without. In 16 cases with detailed MRI description, all tumors showed high density on T1-weighted images and low density on T2-weighted images. Two cases that described contrast-enhanced MRI showed sickly enhancement in the early phase. Both cases had solitary mass, and their tumor sizes were 3 and 6.5 cm, respectively [27, 41]. Our case showed highly enhanced mass in the early phase, but not detected in abdominal US and CT. It is suggested that these findings would be specific to small hepatic MALT lymphoma. With regard to treatment, 31 patients (60.8 %) underwent surgical resection with or without chemotherapy or radiation therapy. Of these, 28 patients had a single tumor, including 4 whose tumors were accidentally discovered in the isolated liver from transplantation patients. In addition, one patient underwent radiofrequency ablation, five received chemotherapy only, and two received radiation only. Eight patients did not receive any treatment, five of whom died during the follow-up period. Recurrence was reported in two patients.
Table 1

Reported cases of hepatic MALT lymphoma

CaseSex/ageHBVHCVConcomitant diseaseTumor no.TreatmentOutcome
1M/66NDNDUreteral cancer1Resection12 M/alive
2F/73NDND(−)1ResectionLost to follow-up
3M/85NDNDProstatic cancer2(−)Death after other surgery
4F/60NDNDLiver cirrhosisMultipleTransplantation12 M/dead
5F/57(−)NDAscariasis1Resection55 M/alive
6M/48(+)NDHepatitis1Resection + Chemotherapy38 M/alive
7F/47(−)(−)Multiple biliary unilocular cysts1Resection + Radiation30 M/alive
8M/64(−)(−)Colon cancer1ResectionLost to follow-up
9F/62(−)(−)Primary biliary cirrhosis1Resection6 M/alive
10F/64(−)(+)Liver cirrhosis1Chemotherapy24 M/alive
11F/65(−)(+)Hepatitis1Chemotherapy48 M/alive
12F/69(−)(−)(−)1ResectionShort time/alive
13F/41(−)(−)Primary biliary cirrhosis1(−)12 M/alive
14F/64(−)(−)(−)1Resection72 M/alive
15F/57(−)(−)Primary biliary cirrhosis1Transplantation9 M/alive
16F/64(−)(−)Ascariasis1ResectionPulmonary recurrence after 96 M
17F/59NDNDNDMultipleResection + ChemotherapyND
18M/61(−)(−)Gastric cancer1Resection18 M/alive
19M/73(−)(+)Liver cirrhosis1Resection34 M/alive
20M/59(−)(+)Hepatitis1Resection30 M/alive
21F/50(−)(−)(−)1Resection + Chemotherapy30 M/alive
22F/72NDNDColon cancer1(−)1 M/dead
23F/61NDNDRheumatoid arthritis1(−)Dead
24F/58NDND(−)MultipleResection + Chemotherapy37 M/alive
25F/62NDNDBreast cancer1Resection9 M/alive
26F/65(+)(−)Hepatocellular carcinoma1Resection10 M/alive
27F/60(−)(−)Gastric MALT lymphoma1(−)30 M/alive
28M/59(+)(−)Liver cirrhosis2Transplantation6 M/Alive
29M/36(+)(−)Hepatitis1ResectionHepatic recurrence after 40 M
30M/53(−)(+)Liver cirrhosisMultipleTransplantation + ChemoND
31M/67(−)(−)Hepatitis (drug)1RadiationPulmonary recurrence after 72 M
32M/69(−)(−)(−)2RFA + Chemo24 M/alive
33F/74(−)(−)(−)1Resection + Chemotherapy6 M/alive
34F/67NANAGastric MALT lymphomaMultiple(−)1 M/dead
35F/72(−)(−)Colon cancer1Resection24 M/alive
36M/64(−)(−)Gastric cancerMultiple(−)24 M/alive
37M/71(−)(−)(−)1Resection15 M/alive
38M/71(−)(−)(−)1Resection + Chemotherapy45 M/alive
39F/56(−)(−)(−)1ResectionPulmonary recurrence after 84 M
40M/59(−)(−)(−)1Resection5 M/alive
41M/86(+)(−)Hepatitis1(−)15 M/alive
42M/58(−)(+)Hepatitis1Resection + Chemotherapy6 M/alive
43F/43(−)(−)Gastric cancer1Resection24 M/alive
44F/80(−)(−)Primary biliary cirrhosisMultipleChemotherapyND
45M/76(−)(+)Hepatitis1Radiation60 M/alive
46F/74(−)(−)Colon cancer2Resection24 M/alive
47F/74(−)(−)Primary biliary cirrhosisMultipleChemotherapy36 M/alive, no relapse
48M/73(−)(+)HepatitisMultipleChemotherapy24 M/alive, relapse
49F/56(−)(−)(−)1Resection13 M/alive
50M/77(−)(+)Hepatitis1Resection8 M/alive
Our caseM/74(−)(−)(−)1Resection30 M/alive

ND not detected

Reported cases of hepatic MALT lymphoma ND not detected According to the abovementioned case reports, primary hepatic MALT lymphoma tends to be solitary and small. Furthermore, it is often difficult to make a definite diagnosis of primary hepatic MALT lymphoma solely based on the imaging findings as the disease seem to exhibit variable imaging features. Therefore, it is necessary to accumulate more cases and establish a therapeutic strategy for primary hepatic MALT lymphoma.

Conclusions

In the present report, we described a case of primary hepatic MALT lymphoma. Our experience in this case and review of relevant literature indicated that preoperative diagnosis of hepatic MALT lymphoma might be challenging because of the disease’s varying imaging features. Thus, further study of this extremely rare disease is necessary.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images.
  32 in total

1.  Primary hepatic lymphoma associated with primary biliary cirrhosis.

Authors:  S Sato; T Masuda; H Oikawa; T Satoh; Y Suzuki; Y Takikawa; K Yamazaki; K Suzuki; S Sato
Journal:  Am J Gastroenterol       Date:  1999-06       Impact factor: 10.864

2.  Hepatic mucosa-associated lymphoid tissue (MALT) lymphoma associated with hepatitis C.

Authors:  Shugo Mizuno; Shuji Isaji; Masami Tabata; Shinji Uemoto; Hiroshi Imai; Katsuya Shiraki
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

3.  [A case of MALT lymphoma of the liver treated by RFA and Rituximab].

Authors:  Maho Hamada; Yoshinori Tanaka; Yuichi Kobayashi; Eiji Takeshita; Kouji Joko
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2006-06

Review 4.  Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type.

Authors:  Catherine Thieblemont; Francesco Bertoni; Christiane Copie-Bergman; Andrés J M Ferreri; Maurilio Ponzoni
Journal:  Semin Cancer Biol       Date:  2013-12-09       Impact factor: 15.707

5.  Primary hepatic B-cell lymphoma of mucosa-associated lymphoid tissue.

Authors:  C M Kirk; D Lewin; J Lazarchick
Journal:  Arch Pathol Lab Med       Date:  1999-08       Impact factor: 5.534

6.  Diagnosis and surgical treatment of primary hepatic lymphoma.

Authors:  Xin-Wei Yang; Wei-Feng Tan; Wen-Long Yu; Song Shi; Yi Wang; You-Lei Zhang; Yong-Jie Zhang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

7.  Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in a liver transplant patient with hepatitis B cirrhosis.

Authors:  D Nart; Y Ertan; F Yilmaz; G Yüce; M Zeytunlu; M Kilic
Journal:  Transplant Proc       Date:  2005-12       Impact factor: 1.066

8.  Primary non-Hodgkin's lymphoma of the main hepatic duct junction.

Authors:  Masaya Shito; Toshihiro Kakefuda; Tai Omori; Seiichiro Ishii; Hitoshi Sugiura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-08-01

9.  Longlasting remission of primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma achieved by radiotherapy alone.

Authors:  Sang Yun Shin; Jin Seok Kim; Jong Keun Lim; Jee Sook Hahn; Woo Ick Yang; Chang Ok Suh
Journal:  Korean J Intern Med       Date:  2006-06       Impact factor: 2.884

10.  High-grade hepatic mucosa-associated lymphoid tissue (MALT) lymphoma probably transformed from the low-grade gastric MALT lymphoma.

Authors:  Yong Woo Chung; Joo Hyun Sohn; Chang Hee Paik; Jae Yoon Jeong; Dong Soo Han; Yong Cheol Jeon; Young Ha Oh
Journal:  Korean J Intern Med       Date:  2006-09       Impact factor: 2.884

View more
  7 in total

1.  Primary hepatic mucosa-associated lymphoid tissue lymphoma: case report and literature review.

Authors:  Zhengqi Fu; Lixia Wu; Jiaming Chen; Qichang Zheng; Ping Li; Li Zhang; Chuanming Zhu; Zhengshou Rao; Shaobo Hu
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

2.  A case of primary hepatic mucosa-associated lymphoid tissue lymphoma incidentally found in the sustained virological response state of chronic hepatitis C: review of the literature of this rare disease.

Authors:  Tadahito Yasuda; Shigeki Nakagawa; Katsunori Imai; Hirohisa Okabe; Hiromitsu Hayashi; Yo-Ichi Yamashita; Akira Chikamoto; Kazutaka Ozono; Yoshiki Mikami; Hideo Baba
Journal:  Int Cancer Conf J       Date:  2020-01-03

3.  Primary mucosa-associated lymphoid tissue lymphoma of the liver: A report of two cases and review of the literature.

Authors:  Ifeyinwa E Obiorah; Lynt Johnson; Metin Ozdemirli
Journal:  World J Hepatol       Date:  2017-01-28

Review 4.  Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: A case report and literature review.

Authors:  Shuilin Dong; Lin Chen; Yifa Chen; Xiaoping Chen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Primary Hepatic Lymphoma Mimicking a Hepatocellular Carcinoma in a Cirrhotic Patient: Case Report and Systematic Review of the Literature.

Authors:  Ali Bohlok; Thierry De Grez; Fikri Bouazza; Roland De Wind; Melody El-Khoury; Deborah Repullo; Vincent Donckier
Journal:  Case Rep Surg       Date:  2018-04-10

Review 6.  Primary hepatic mucosa-associated lymphoid tissue lymphoma: A case report and literature review.

Authors:  Huazhi Xie; Jian Lv; Yong Ji; Xinjian Du; Xin Yang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 7.  Primary hepatopancreatobiliary lymphoma: Pathogenesis, diagnosis, and management.

Authors:  Qianwen Wang; Kangze Wu; Xuzhao Zhang; Yang Liu; Zhouyi Sun; Shumei Wei; Bo Zhang
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.